Company intelligence / Profile preview

DarwinHealth

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

DarwinHealth’s core platform and tools (including DarwinOncoTarget and DarwinOncoTreat) have been validated in clinical trials and peer-reviewed publications, such as results in 2024 demonstrating 100% accuracy for predicting HDAC6 inhibitor response in breast cancer and 91% accuracy for predicting response in multiple tumor types. Their technologies are deployed in hundreds of cancer patients in the US and Europe powering trials in rare and treatment-refractory cancers.

Therapeutic areas: Oncology
Industry: Digital Health Medical Devices

Partnerships

Daiichi SankyoCelgeneBristol Myers SquibbPrelude Therapeutics

Beyond the preview

Go deeper on DarwinHealth.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DarwinHealth.

Explore the full profile